Observations that naturally occurring inactivating mutations of the myostatin gene are associated with increased muscle mass \[[@B1]\] have stimulated substantial pharmaceutical efforts to develop drugs that inhibit myostatin action or signaling through the ActRIIB receptor to treat and prevent the loss of muscle mass and function during aging and chronic illness, such as that associated with HIV infection, chronic obstructive lung disease, injury, or end-stage renal disease \[[@B4]\]. A number of inhibitors of myostatin and activins that block signaling through the ActRIIB receptor are undergoing efficacy trials in humans for these and other indications \[[@B7]\]. An important safety issue with respect to the long-term therapeutic applications of these drugs is whether these compounds induce myocardial hypertrophy and impair cardiac function \[[@B10]\]. The aim of this investigation was to determine the effects of an ActRIIB ligand trap, an inhibitor of myostatin, activins, and some other members of the TGF-*β* superfamily, on measures of myocardial mass and function using a primate model of simian immunodeficiency virus (SIV)-induced weight loss and muscle wasting \[[@B11]\].

Myostatin is expressed in the myocardium \[[@B12]\], and its myocardial expression is upregulated in cardiac ischemia and heart failure \[[@B12], [@B13]\]. Furthermore, myostatin has been reported to inhibit IGF-1--stimulated proliferation and hypertrophy of cardiomyocytes \[[@B14]\]. Therefore, inactivation of myostatin would be expected to increase myocardial mass. However, previous studies of the effects of genetic disruption of myostatin on the heart in rodents have yielded conflicting results \[[@B16]\]. Some studies have reported myocardial hypertrophy in myostatin-null mice \[[@B17]\], but others found no significant differences in myocardial mass between wild-type and myostatin-disrupted mice \[[@B16], [@B21], [@B22]\]. One study reported signs of dilated cardiomyopathy at rest, including lower strain measurements in myostatin-null mice compared with wild-type mice \[[@B18]\]. Interestingly, however, adrenergic stimulation with isoproterenol revealed enhanced responsiveness in aged myostatin-null mice \[[@B18]\], a sign of increased maximal cardiac functional reserve. Still others have found the myocardial function to be normal \[[@B19], [@B20]\]. The reasons for these differences in the results from different laboratories are not entirely clear, but differences in mouse strains, experimental models, and measurement techniques could contribute to heterogeneity of results.

Accordingly, we determined the effects of an ActRIIB Fc fusion protein (ActRIIB.Fc)-mediated inhibition of myostatin and other TGF-*β*/activin family members on myocardial mass and cardiac function using a primate model of acquired immunodeficiency syndrome. The primary aim of this project was to test the hypothesis that administration of ActRIIB.Fc ligand trap would reverse the weight loss and muscle wasting that occurs with the development of acquired immunodeficiency syndrome in SIV-infected juvenile rhesus macaques. Juvenile macaques experience a failure to thrive when inoculated with SIV similar to that observed in HIV-infected children \[[@B23]\], and the SIV model closely parallels the human disease \[[@B24], [@B25]\]. The results of the efficacy analyses demonstrating the reversal of SIV-associated loss of body weight and muscle mass by ActRIIB.Fc administration have been published \[[@B11]\], as have its effects in bone mineral content and density \[[@B26]\]. Here we describe the results of the prespecified secondary analyses of the cardiac safety data, assessed using two-dimensional echocardiography.

1. Methods {#s1}
==========

The detailed study protocol has been published \[[@B11]\]. The study protocol was approved by Harvard Medical School's Standing Committee on Animals. The animals were pair-housed in a centralized Animal Biological Safety Level 2 facility at the New England Primate Research Center and were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, 2011). The macaques were fed a certified commercial primate diet (8714; Teklad, Harlan Laboratories, South Easton, MA) and provided fresh water *ad libitum*.

A. Animals {#s2}
----------

Fourteen male juvenile (2.5 to 3 years) rhesus macaques (*Macaca mulatta*) were studied. Animals were allocated randomly balancing the groups for age and major histocompatibility complex status. The macaques were intravenously inoculated with SIVmac239 (50 ng of p27 viral-antigen equivalent); the day of inoculation was considered day 1. Seven macaques were assigned to receive either ActRIIB.Fc (10 mg/kg/wk), an experimental grade ligand trap kindly provided by Dr. Carl Morris (Pfizer, Inc., Cambridge, MA), or a saline placebo by intramuscular injection weekly for 12 weeks starting 4 weeks after SIV inoculation.

B. Echocardiography {#s3}
-------------------

Two-dimensional and spectral Doppler echocardiography was performed at baseline (week 4) and after 12 weeks of intervention (16 weeks postinoculation). Animals were sedated with Telazol 5 mg/kg intramuscularly before echocardiography. M-mode, two-dimensional echocardiograms were performed by a veterinary cardiologist (Nancy Morris, DVM), who was blind to treatment allocation of animals. Each animal underwent a comprehensive transthoracic scanning with two-dimensional, M-mode, and pulsed-wave Doppler echocardiography using an ultrasound system (General Electric Vivid P, GE Medical Systems Ultrasound and Primary Care Diagnostics, LLC, Wauwatosa, WI). Digital echocardiographic images were captured and stored for later analysis; both still images and digital loops containing three cardiac cycles were saved. The best images captured on each animal were used to perform replicate measurements of each parameter, using leading edge measurement technique to obtain an average value. End-systolic and end-diastolic left ventricular (LV) dimensions and interventricular septum thickness and LV posterior wall thickness in systole and diastole were measured using M-mode tracing from the right parasternal short-axis views. Heart rates were recorded on each monkey. Fractional shortening (FS), ejection fraction (EF), cardiac output, cardiac index, end-diastolic volume, end-systolic volume, and stroke volume were calculated from LV diastolic and systolic measurements, using Teichholz methodology, in accordance with echocardiography guidelines published by the American Society of Echocardiography guidelines \[[@B27]\]. Left atrial maximal dimension and aortic root diameter were measured by M-mode echocardiography from the parasternal long-axis view. Color flow Doppler was used to interrogate pulmonary, aortic, mitral, and tricuspid valves to screen for leaks in valves. Pulsed-wave Doppler was used to determine peak aortic and pulmonary flow velocities. The left parasternal images were used to measure peak mitral E and A inflow velocities.

C. Western Blot Analyses {#s4}
------------------------

LV samples were obtained from midventricular short axis of the hearts during euthanasia and frozen at −80°C until analyzed. Pulverized LV muscle was homogenized in 1× cell lysis buffer (\#9803; Cell Signaling Technology, Beverly, MA) supplemented with 0.1% SDS and 1 mM phenylmethane sulfonyl fluoride. Primary antibodies for calsequestrin (RRID: [AB_2071448](http://antibodyregistry.org/search.php?q=AB_2071448)) \[[@B28]\] and *β*-actin (RRID: [AB_2714189](http://antibodyregistry.org/search.php?q=AB_2714189)) \[[@B29]\] were obtained from Santa Cruz Biotechnology, Santa Cruz, CA. Antibodies for phospholamban (RRID: [AB_10949105](http://antibodyregistry.org/search.php?q=AB_10949105)) \[[@B30]\], phosphorylated phospholamban (Ser16/Th17; RRID: [AB_10949102](http://antibodyregistry.org/search.php?q=AB_10949102)) \[[@B31]\], sarcoplasmic calcium ATPase (SERCA)-1 (RRID: [AB_2728695](http://antibodyregistry.org/search.php?q=AB_2728695)) \[[@B32]\], SERCA2a (RRID: [AB_10827913](http://antibodyregistry.org/search.php?q=AB_10827913)) \[[@B33]\], protein kinase A-catalytic *α* subunit (RRID: [AB_10706172](http://antibodyregistry.org/search.php?q=AB_10706172)) \[[@B34]\], and phospho-protein kinase A-catalytic *α* (PKA-C*α*) (RRID: [AB_10707163](http://antibodyregistry.org/search.php?q=AB_10707163)) \[[@B35]\] were obtained from Cell Signaling Technology. Proteins were separated by SDS-PAGE, transferred to a polyvinylidene difluoride membrane, blocked in 5% milk, and incubated with the first antibody overnight at 4°C with gentle shaking using a 1:1000 dilution ratio. The membrane was washed and incubated in second antibody at room temperature for 1 hour at a 1:4000 dilution ratio. Proteins were detected by exposure to X-ray film after incubation with LumiGLO (\#7003; Cell Signaling Technology) and quantified by densitometry using National Institutes of Health ImageJ software.

D. RT-qPCR {#s5}
----------

Pulverized LV muscle was homogenized in Trizol (\#15596018; Invitrogen, Carlsbad, CA) and RNA was extracted using the RNeasy plus mini kit (\#74134; Qiagen, Valencia, CA). Residual genomic DNA was removed using the vendor-provided genomic DNA eliminator columns. Single-strand cDNA was synthesized using ProtoScript First Strand cDNA Synthesis Kit (\#E6300S; New England Biolabs, Ipswich, MA) following the manufacturer's instruction. SYBR-based quantitative PCR was performed using a 7500 Sequence Detection System (Thermo Fisher Scientific, Waltham, MA). The primer sequences are listed in [Supplemental Table 1](#sup1){ref-type="supplementary-material"}.

E. Histopathology {#s6}
-----------------

For the histopathological evaluation of the left ventricle for myocardial fibrosis, the tissue was removed immediately after euthanasia and midventricular short-axis heart section fixed in 4.0% paraformaldehyde neutral buffer solution. Tissues were dehydrated, embedded in paraffin, sectioned at a 2-μm thickness, and stained using Masson's trichrome. The relative extent of cardiac fibrosis within each sample was evaluated by an experienced pathologist using a light microscope and scored as 0, 1, or 2 for no, medium, or high myocardial fibrosis, respectively. Digital evaluation of fibrosis was also performed. Three randomly selected fields were analyzed digitally for each sample. The trichrome-stained sections were scanned in an inverted microscope (Eclipse TE2000, Nikon Instruments Inc., Melville, NY) equipped with a SPOT 7.4 Slider RTKE camera (Diagnostic Instruments Inc., Sterling Heights, MI). Images at ×20 magnification were used for digital quantification analysis. Percent fibrosis was determined using the batch mode of the ImageJ software macro \[[@B36]\].

F. Statistical Analyses {#s7}
-----------------------

Baseline characteristics of animals at week 4 are expressed as mean and SDs. Analysis of covariance with an intervention factor (ActRIIB.Fc or saline), adjusted to baseline value, was performed to assess the effect of intervention at week 16. Echocardiographic measures of myocardial mass and function were calculated as the change from baseline. Sensitivity analyses excluding two animals with early onset of puberty were conducted to investigate robustness of our findings. Unpaired *t* test was used for comparison between expression levels of myocardial mRNA and proteins between treatment arms. All data in graphs are presented as mean ± SEM. Statistical analyses were performed using Prism (version 4.0c; GraphPad Software Incorporated, La Jolla, CA) and SAS software (version 9.3; SAS Institute, Cary, NC).

2. Results {#s8}
==========

A. Baseline Characteristics and Overall Health {#s9}
----------------------------------------------

As reported previously, one animal demonstrating rapid progression to simian AIDS in the active intervention arm was euthanized at 14 weeks after SIV inoculation and excluded from analysis \[[@B11]\]. This event was consistent with the expected 5% incidence of rapid progression following inoculation with SIVmac239 \[[@B37]\]. No other animals showed any signs of clinical illness. The analytical sample for the echocardiographic safety analysis included all 13 animals, which had baseline and week 16 echocardiography. As reported previously, two animals (one in each intervention group) developed unusually high serum testosterone levels that were higher than those in the other animals \[[@B26]\], suggestive of earlier than expected onset of puberty. We performed additional sensitivity analyses after excluding these two animals with early onset of puberty, and the results were similar ([Supplemental Table 2](#sup1){ref-type="supplementary-material"}).

Because of the differences in age and baseline body weight in both groups, there was some variation in baseline measures of cardiac dimensions and function in both groups ([Table 1](#T1){ref-type="table"}). The plasma SIV copy numbers, CD4^+^ and CD8^+^ T lymphocyte counts, body weight, and body composition were similar between the two groups, as was reported previously \[[@B11]\].

###### 

Baseline Characteristics of the Animals

                                                       ActRIIB.Fc (n = 6)   Control (n = 7)
  ---------------------------------------------------- -------------------- -----------------
  Somatometrics                                                             
   Body weight, kg                                     4.2 ± 0.4            3.9 ± 0.7
   Body surface area, cm^2^                            2516 ± 156           2376 ± 219
  Cardiac dimensions                                                        
   LV internal diameter at diastole, cm                1.80 ± 0.12          1.71 ± 0.18
   LV internal diameter at systole, cm                 1.10 ± 0.16          1.04 ± 0.15
   Interventricular septum thickness at diastole, cm   0.42 ± 0.03          0.41 ± 0.03
   Interventricular septum thickness at systole, cm    0.67 ± 0.12          0.65 ± 0.09
   LV posterior wall thickness at diastole, cm         0.41 ± 0.04          0.40 ± 0.04
   LV posterior wall thickness at systole, cm          0.63 ± 0.09          0.65 ± 0.02
   Left atrium diameter, cm                            1.10 ± 0.13          1.10 ± 0.13
   Aortic root diameter, cm                            0.96 ± 0.04          0.93 ± 0.08
   Left atrium:aorta ratio                             1.16 ± 0.15          1.19 ± 0.12
  Cardiac function                                                          
   Heart rate, beats/min                               140 ± 15             147 ± 21
   End-diastolic volume, mL                            9.8 ± 1.7            8.6 ± 2.2
   End-diastolic volume index, mL/m^2^                 0.0039 ± 0.0007      0.0036 ± 0.0007
   Stroke volume, mL                                   7.0 ± 1.3            6.2 ± 1.6
   End-systolic volume, mL                             2.8 ± 1.2            2.4 ± 0.9
   End-systolic volume index, mL/m^2^                  0.0011 ± 0.0005      0.0010 ± 0.0004
   Fractional shortening, %                            38.6 ± 6.7           38.9 ± 4.8
   Ejection fraction, %                                71.6 ± 8.2           72.5 ± 6.0
   Cardiac output, mL/min                              961 ± 105            899 ± 187
   Cardiac index, mL/min/m^2^                          0.384 ± 0.046        0.378 ± 0.069

Data are displayed as mean ± SD of characteristics at week 4 (before treatment initiation), except for plasma SIV copy number, which represents quantification at week 2. The baseline data on body weight and body surface area have been reported previously \[[@B25]\] and are shown here only to provide a perspective of the myocardial dimensions in relation to the animal's body size.

Abbreviations: LV, left ventricular; SIV, simian immunodeficiency virus.

B. Effects on Myocardial Mass and Chamber Size {#s10}
----------------------------------------------

Mean ± SEM cardiac weight at necropsy was slightly higher in ActRIIB.Fc-treated animals (22.5 ± 2.2 g in ActRIIB *vs.* 18.9 ± 2.6 g in the placebo group), but the difference was not statistically significant (*P* = 0.199). Additionally, the ratio of heart weight to total body weight was similar between groups (4.9 ± 0.4% in ActRIIB.Fc group *vs.* 4.8 ± 0.2% in placebo group; *P* = 0.832), suggesting that the slightly increased myocardial mass was proportional to the ActRIIB.Fc-induced increase in body weight. Compared with the placebo injection, the administration of ActRIIB.Fc was associated with a significantly greater increase in the interventricular septal thickness during diastole (*P* = 0.010; [Table 2](#T2){ref-type="table"}) and systole (*P* = 0.036) ([Fig. 1](#F1){ref-type="fig"}). Similarly, the LV posterior wall thickness increased more in the ActRIIB.Fc-treated macaques than in vehicle-treated animals both during diastole (*P* = 0.002) and systole (*P* = 0.044; [Fig. 1](#F1){ref-type="fig"}). However, the changes in the LV internal diameter did not differ significantly between the two intervention groups either during diastole (*P* = 0.555) or during systole (*P* = 0.290; [Fig. 1](#F1){ref-type="fig"}). The two intervention groups also did not differ significantly in the changes from baseline in left atrial and aortic root dimensions.

###### 

Change From Baseline in Measures of Cardiac Dimensions and Cardiac Function by Treatment Arm

                                                       ActRIIB.Fc         Control              Difference         *P* Value
  ---------------------------------------------------- ------------------ -------------------- ------------------ -----------
  Somatometrics                                                                                                   
   Body weight, kg                                     0.526 ± 0.112      0.049 ± 0.104        0.477 ± 0.156      0.012
   Body surface area, cm^2^                            186.2 ± 46.8       52.1 ± 43.1          134.1 ± 65.9       0.069
  Cardiac dimensions                                                                                              
   LV internal diameter at diastole, cm                0.013 ± 0.053      0.058 ± 0.049        −0.045 ± 0.073     0.555
   LV Internal diameter at systole, cm                 −0.105 ± 0.044     −0.037 ± 0.041       −0.068 ± 0.061     0.290
   Interventricular septum thickness at diastole, cm   0.113 ± 0.024      0.008 ± 0.023        0.105 ± 0.033      0.010
   Interventricular septum thickness at systole, cm    0.105 ± 0.037      −0.020 ± 0.034       0.124 ± 0.051      0.036
   LV posterior wall at diastole, cm                   0.109 ± 0.022      −0.013 ± 0.020       0.122 ± 0.030      0.002
   LV posterior wall at systole, cm                    0.169 ± 0.046      0.022 ± 0.043        0.146 ± 0.063      0.044
   Left atrium diameter, cm                            0.173 ± 0.058      0.044 ± 0.053        0.129 ± 0.079      0.133
   Aortic root diameter, cm                            0.032 ± 0.027      0.005 ± 0.025        0.027 ± 0.037      0.489
   Left atrium:aorta ratio                             0.137 ± 0.058      0.043 ± 0.054        0.094 ± 0.080      0.268
  Cardiac function                                                                                                
   Heart rate, beats/min                               28.2 ± 8.7         −7.1 ± 8.0           35.3 ± 12.0        0.015
   End-diastolic volume, mL                            −1.17 ± 1.05       0.97 ± 0.97          −2.14 ± 1.46       0.174
   End-diastolic volume index, mL/m^2^                 −0.0007 ± 0.0004   0.0003 ± 0.0004      −0.001 ± 0.0006    0.078
   Stroke volume, mL                                   1.07 ± 0.67        0.79 ± 0.62          0.28 ± 0.93        0.770
   End-systolic volume, mL                             −0.689 ± 0.238     −0.148 ± 0.220       −0.542 ± 0.328     0.129
   End-systolic volume index, mL/m^2^                  −0.0003 ± 0.0001   −0.00006 ± 0.00009   −0.0003 ± 0.0001   0.054
   Fractional shortening, %                            6.54 ± 1.88        4.20 ± 1.74          2.34 ± 2.56        0.381
   Ejection fraction, %                                7.47 ± 2.36        2.49 ± 2.18          4.98 ± 3.22        0.153
   Cardiac output, mL/min                              390.7 ± 133.8      82.1 ± 123.6         308.6 ± 184.2      0.125
   Cardiac index, mL/min/m^2^                          0.106 ± 0.049      0.037 ± 0.046        0.069 ± 0.067      0.328

Estimated means and 95% CIs by treatment arm and for the difference between groups. Effects expressed as change from baseline and derived from the analysis of covariance model. *P* value for difference between groups in changes from baseline.

Abbreviations: CI, confidence interval; LV, left ventricular.

![Changes in (A) body weight, (B) body surface area, (C) left atrium, (D) LV internal dimension at diastole, (E) LV internal dimension at systole, (F) aorta, (G) interventricular septum thickness at diastole, (H) interventricular septum thickness at systole, (I) left atrium:aorta ratio, (J) LV posterior wall thickness at diastole, and (K) LV posterior wall thickness at systole in both groups during the study. Data presented are means; error bars are SEM. The weeks represent time after SIV inoculation. Week 4 data represent the baseline data collected 4 weeks after SIV inoculation but immediately before starting the study interventions (ActRIIB.Fc or saline injections); week 16 data represent data collected after 12 weeks of intervention. LV, left ventricular; SIV, simian immunodeficiency virus.](js.2018-00099f1){#F1}

C. Effects on Measures of Myocardial Contractile Function {#s11}
---------------------------------------------------------

There was a greater increase in heart rate in ActRIIB.Fc-treated animals compared with the placebo-treated animals (*P* = 0.015). The change in cardiac output from baseline was numerically greater in animals treated with ActRIIB.Fc, but between-group differences were not statistically significant (*P* = 0.125; [Fig. 2](#F2){ref-type="fig"}). The changes in cardiac index (cardiac output divided by body surface area) did not differ significantly between the two groups (*P* = 0.328; [Fig. 2](#F2){ref-type="fig"}; [Table 2](#T2){ref-type="table"}), suggesting that the changes in cardiac output were proportional to the change in body size in the two groups. The EF changed minimally from baseline, and the changes did not differ significantly between groups (*P* = 0.153). Similarly, the two groups did not differ in either the change in stroke volume (*P* = 0.770) or in FS ([Fig. 2](#F2){ref-type="fig"}). The changes in end-diastolic and end-systolic volumes did not differ between groups (*P* = 0.174 and 0.129 for end-diastolic and end-systolic volumes, respectively) with or without correction for body mass ([Table 2](#T2){ref-type="table"}).

![Changes in (A) heart rate, (B) end-diastolic volume, (C) end-diastolic volume index, (D) stroke volume, (E) end-systolic volume, (F) end-systolic volume index, (G) fractional shortening, (H) ejection fraction, (I) cardiac output, and (J) cardiac index in both groups along the study. Data presented are means; error bars are SEM. The weeks represent time after SIV inoculation. Week 4 data represent the baseline data collected 4 weeks after SIV inoculation but immediately before starting the study interventions (ActRIIB.Fc or saline injections).](js.2018-00099f2){#F2}

D. Effects on the Expression Levels of Myocardial Proteins {#s12}
----------------------------------------------------------

Because one animal in each group had signs of early-onset puberty, we excluded these animals from the analyses on expression levels of myocardial proteins because higher testosterone levels might potentially independently affect myocardial gene expression. The RT-quantitative PCR analyses of LV myocardial tissue revealed reduced mRNA expression level of IGF-1, an important factor in the maintenance of normal cardiac structure and function, in animals treated with ActRIIB.Fc relative to controls. This could be a result of compensatory repression caused by the increase in myocardial mass in the ActRIIB.Fc-treated group. However, the mRNA expression levels of myostatin, its downstream target PAI-1, and inflammation markers IL-6 and TNF-*α* did not differ between the two groups. The expression of NADH-coenzyme Q reductase, a key protein in the complex I of the mitochondrial electron transport chain, also did not differ between the two groups ([Fig. 3](#F3){ref-type="fig"}).

![Effects of ActRIIB.Fc or placebo on myocardial expression of (A) IGF-1, (B) NADH-coenzyme Q reductase, (C) myostatin, (D) PAI-1, (E) IL-6, and (F) TNF-*α* in SIV-infected juvenile male rhesus macaques (n = 5 for ActRIIB.Fc; n = 6 for control). CoQ_R, NADH-coenzyme Q reductase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.](js.2018-00099f3){#F3}

Sarcoplasmic calcium ATPase in fast-twitching (SERCA1) and slow twitching (SERCA2) cardiac myofibers play an important role in the regulation of contractile function in healthy and diseased heart. Aging-related decline in SERCA2 has been linked to myocardial dysfunction \[[@B38], [@B39]\]. However, aberrant increase in SERCA1/2 and consequent deregulation of calcium intake are also known to be linked to cardiac hypertrophy \[[@B40], [@B41]\]. Western analysis of LV myocardial tissue revealed a modestly higher protein levels of SERCA1 and SERCA2 in ActRIIB.Fc-treated macaques than in vehicle-treated macaques ([Fig. 4](#F4){ref-type="fig"}), in agreement with prior findings in myostatin-null mice \[[@B17], [@B42]\]. Phospholamban (PhLB) is a sarcoplasmic reticulum membrane protein that regulates calcium uptake through inhibition of SERCA activity \[[@B43]\]. PhLB is negatively regulated by its phosphorylation (Ser16/Th17) mediated by PKA \[[@B45], [@B46]\]. As shown in [Fig. 4](#F4){ref-type="fig"}, ActRIIB.Fc treatment was associated with an increase in PhLB expression and a decrease in phos-PhLB, which resulted in an even greater decrease in the PhosPhLB:PhLB ratio, suggesting the suppression of SERCA activity. The expression of PKA and phospho-PKA, the upstream kinase that phosphorylates PhLB, did not differ between the placebo and ActRIIB.Fc-treated groups \[[@B47]\].

![Effects of ActRIIB.Fc or placebo on myocardial protein content of calcium-handling proteins evaluated by western blot. Bars represent means; error bars are SEM of averaged duplicate measurements for each animal (n = 5 for ActRIIB.Fc; n = 6 for control). a.u. = arbitrary units; PhLB, phospholamban; PKA, protein kinase A; SERCA1, sarcoplasmic calcium ATPase in fast-twitching cardiac myofiber; SERCA2, sarcoplasmic calcium ATPase in slow-twitching cardiac myofiber.](js.2018-00099f4){#F4}

In addition to the altered expression of PhLB and SERCA1/2, the ActRIIB.Fc-treated group also exhibited a modestly increased expression of calsequestrin, a calcium-binding protein that holds calcium in the cisterna of the sarcoplasmic reticulum. This observation is consistent with similar prior observation in mice \[[@B17], [@B42]\].

E. Effects on Myocardial Fibrosis {#s13}
---------------------------------

Increased cardiomyocyte myostatin expression has been reported to induce myocardial fibrosis \[[@B48]\], and inhibition of the myostatin pathway has been proposed as a potential therapeutic approach for fibrotic cardiomyopathies \[[@B49]\]. Because both SIV and HIV infections have been associated with myocardial fibrosis \[[@B50]\], and myostatin expression is increased in HIV \[[@B53]\], we evaluated the effects of ActRIIB.Fc on myocardial fibrosis compared with placebo. Tissue fibrosis was assessed using Masson's trichrome staining. The results were analyzed by visual scoring and by digital quantification. As shown in [Fig. 5](#F5){ref-type="fig"}, there was considerable variation in the level of fibrosis in both groups, with no significant difference in the mean fibrosis score between the two groups, visually or by digital quantification (*P* = 0.8).

![(Top) Examples of medium (left) and high (right) degree of myocardial fibrosis by visual scoring. (Bottom) Means and error bars are SEM for the scores in myocardial fibrosis by visual score (left) and digital score (right).](js.2018-00099f5){#F5}

3. Discussion {#s14}
=============

We show here that weekly administration of ActRIIB.Fc for 12 weeks to juvenile SIV-infected rhesus macaques was associated with an increase in some measures of myocardial mass but did not adversely affect overall cardiac function. Additionally, there was no substantial between-group difference in LV myocardial fibrosis or in myocardial expression of inflammatory cytokines IL-6 and TNF-*α*. However, complex changes were observed in the expression of several important proteins involved in calcium transfer and storage, similar to those reported earlier in the cardiac tissue of myostatin-null mice \[[@B42]\]. These data, together with the previous reports of the effects on the skeletal muscle and bone of SIV-infected macaques \[[@B11], [@B26]\], suggest that ActRIIB.Fc might be a viable therapeutic option for the treatment of muscle-wasting conditions. Although these findings are reassuring, intervention studies of longer duration are needed to establish the long-term cardiac safety of this class of drugs.

The increased thickness of intraventricular septum and LV posterior wall in ActRIIB.Fc-treated animals compared with control group suggests mild LV hypertrophy, similar to some reports in myostatin-null mice \[[@B17]\]. The proportion of myocardial mass to total body weight was similar between the placebo and the treated groups, suggesting that the numerically higher myocardial mass in ActRIIB.Fc-treated animals could be an adaptation to the increased whole-body muscle mass and body weight. However, the changes in LV internal dimensions, stroke volume, EF, and FS were similar between groups, suggesting preserved cardiac function in juvenile macaques treated with ActRIIB.Fc. Similar cardiac remodeling with eccentric hypertrophy is observed in some athletes, particularly in runners, who typically develop thicker LV myocardium without changes in LV chamber volume \[[@B54], [@B55]\]. This observation differs from the prior observation of an increase in atrial:body weight and ventricle:body weight ratios in transgenic mice expressing a dominant negative myostatin \[[@B42], [@B56]\]. However, because of the relatively short experimental time frame used in the current study, it remains unknown whether pathological cardiac hypertrophy leading to myocardial dysfunction may develop after prolonged treatment, as found in some studies of myostatin-null mice and the transgenic mice expressing a dominant negative myostatin \[[@B18], [@B56]\].

Some previous studies in rodents have reported findings suggestive of eccentric hypertrophy with myostatin disruption \[[@B17], [@B18]\]. Rodgers *et al.* observed that 7-month-old myostatin-null mice had increased LV myocardial mass, as well as increased LV internal volume at diastole and systole, although stroke volume was similar between the myostatin-null mice and the wild-type mice \[[@B17]\]. Adrenergic stimulation with isoproterenol increased stroke volume in myostatin-null mice, contrasting with the reduction observed in wild-type mice \[[@B17]\], suggesting increased stress-induced relaxation and contractile capacity, a characteristic feature of physiologic myocardial hypertrophy. Similar findings were later reported by Jackson *et al.* in aging (13 months of age) myostatin-null mice \[[@B18]\]. Some other studies in rodents have reported the absence of LV hypertrophy with myostatin disruption \[[@B20]\]. Interestingly, baseline chamber dimensions and cardiac function in young (8 to 10 weeks old) myostatin-null mice were similar to wild-type \[[@B16]\], whereas in 27- to 37-month-old myostatin-null mice, LV chamber was smaller and FS was greater than in wild-type mice \[[@B20]\]. Taken together, these findings in mice suggest that myostatin disruption leads to the development of mild LV hypertrophy early in adulthood that diminishes with aging, whereas functional (contractile) reserve progressively increases compared with wild-type animals \[[@B18]\]. The cardiac phenotype observed in juvenile macaques treated with ActRIIB.Fc in the current study is similar to the mild cardiac hypertrophy reported in young adult myostatin-null mice.

The slightly numerically higher cardiac output in the ActRIIB.Fc group was not statistically different from that in the control group, and could be largely explained by the higher heart rate in those animals during the week 16 examination. We do not know if this difference in heart rate was compensatory to the increased oxygen demand associated with the treatment-induced gain in lean body mass \[[@B11]\] or whether this was an incidental finding. We observed changes in the expression pattern of proteins related to myocardial calcium regulation and contractility that suggest increased myocardial contractile activity; these are in agreement with previous observations in myostatin-null mice \[[@B42]\] and reflect the expected action of ActRIIB.Fc. The increase in myocardial SERCA2 and calsequestrin protein levels, along with decreased abundance of phosphorylated phospholamban, are not dissimilar from the alterations in myocardial SERCA2 function observed with exercise training \[[@B57]\]; reduced SERCA2 expression is associated with impaired cardiac function \[[@B58]\], and cardiac SERCA2 and calsequestrin protein levels decrease with aging \[[@B38], [@B59]\]. However, the changes in SERCA2 and calsequestrin protein levels and the between-group differences in the expression levels of these proteins were small and could have been a chance finding.

We did not observe significant differences in myocardial fibrosis in macaques treated with ActRIIB.Fc, similar to the observations by Cohn *et al.* in a dystrophin-deficient myostatin-null mouse model \[[@B21]\]. Moreover, the transcript levels of cytokines IL-6 and TNF-*α* were not significantly different between groups. These cytokines as well as myostatin have been previously implicated in myocardial fibrosis \[[@B48], [@B60], [@B61]\].

The current study reports the cardiac effects of ActRIIB.Fc treatment in a nonhuman primate model. The study, however, had some limitations. The sample size was small, which might have resulted in a lack of power do detect small between-group differences. The intervention duration of 12 weeks was relatively short. Additionally, it included male macaques only; the cardiac effects of myostatin signaling disruption in mice has been shown to have substantial sexual dimorphism, particularly on cardiac function \[[@B18]\] and on cardiac expression of some calcium-handling proteins \[[@B42]\]. Nonetheless, the preserved myocardial function and the absence of substantial myocardial fibrosis in ActRIIB.Fc-treated male juvenile macaques in this proof-of-concept study are reassuring and suggest that short-term treatment with ActRIIB.Fc does not impair myocardial function.

In conclusion, weekly intramuscular administration of ActRIIB.Fc at 10 mg/kg for 12 weeks to juvenile SIV-infected rhesus macaques was associated with an increase in some measures of myocardial mass, but did not adversely affect overall myocardial function, suggesting mild myocardial hypertrophy. Further studies of longer duration in a larger number of animals of both sexes are needed to establish the long-term cardiac safety and efficacy of ActRIIB.Fc for muscle-wasting conditions. We have previously reported that this ActRIIB.Fc ligand trap was efficacious in increasing whole body and regional lean body mass; reversing SIV-associated weight loss and promoting body weight gain; and in preventing SIV-associated bone loss and increasing bone mineral content with treatment effect sizes varying from 1.06 to 2.3 SD units \[[@B11], [@B26]\]. Thus, this ActRIIB.Fc ligand trap is a dual muscle and bone anabolic agent, which would be useful in the treatment of conditions associated with loss of muscle and bone, such as HIV-associated wasting; muscle and bone loss associated with androgen deprivation therapy of men with prostate cancer; and age-associated loss of muscle and bone mass. In light of the reassuring short-term myocardial safety data reported here, randomized trials of the compound are indicated for conditions in which the dual muscle and bone anabolic properties might be valuable.
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ActRIIB.Fc

:   ActRIIB receptor Fc fusion protein

EF

:   ejection fraction

FS

:   fractional shortening

LV

:   left ventricular

PhLB

:   phospholamban

PKA

:   protein kinase A

SERCA

:   sarcoplasmic calcium ATPase
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